Pharmaceuticals, Biotechnology and Life Sciences
French biotechnology company Lysogene has kicked off well with its initial public offering on Euronext Paris stock market by raising €22.6 million.
US Government Services Administration (GSA) has awarded MDxHealth to supply Department of Veterans Affairs (VA) with ConfirmMDx for Prostate Cancer.
Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, issued press release to clarify information regarding the Relive trial design and conduct and, in particular, the role of its Data Safety and Monitoring Board (DSMB).
Allergy Therapeutics has appointed Jeff Barton to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.
OptiBiotix Health has been notified by from warrant holders to exercise warrants over 16,351 ordinary shares
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
Teva ‘s chief executive officer Erez Vigodman has stepped down from its position, and the Israel’s largest drugmaker has appointed Dr. Yitzhak Peterburg, who has served as Chairman of the Teva’s Board since January 2015, as Interim President CEO.
Nanobiotix has appointmented Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)